Ebola survivors under the microscope: what happens after recovery?
NCT ID NCT04409405
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed study in the Democratic Republic of the Congo followed 787 people who survived Ebola and their close contacts. Researchers tracked their health over time, looking for lingering virus, immune responses, and other infections. The goal was to better understand the long-term consequences of Ebola and how to prevent further spread.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could improve how we monitor and care for Ebola survivors and help prevent future outbreaks by understanding how the virus lingers or spreads.
- What could go wrong
- This is an observational study, not a treatment trial. It cannot prove that any intervention works, and results may not apply to other regions or outbreaks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
787 people
The number who actually took part.
- Started
-
Apr 2020
- Finished
-
Oct 2021
- Lead sponsor
-
A government agency
The lead sponsor is a government body.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Cured patients: study team will approach every declared-cured EBOV-infection patients discharged of a Ebola treatment center (Beni, Butembo, Mambassa or Mangina), older than 5 year old Contact participants: Cured participants will identify contact with who they were in contact when ill.
- Ages
-
5 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: In cured population * Age ≥ 5 years * Adults and children after an acute episode declared cured of biologically confirmed Ebola virus disease (two negative PCRs are required at least 24 hours apart so that a patient without clinical symptoms can leave the Ebola treatment center), * Informed consent signed by at least one of the two parents or the legal guardian authorizing the child's participation in the study, * Volunteer participant who signed the informed consent for adults. In CONTACT population * Age ≥ 5 years, * Be a contact person of a cured patient (ie patient with a proven EVD, and with two negative PCRs at least 24 hours apart) included in the cohort of Ebola Winners. Based on WHO recommendations and the Centers for Disease Control and Prevention for the identification and traceability of contact subjects: a contact person is defined as a person who encountered the index case during his EVD in his residence, ie having the same place of life as him, * Have not been diagnosed with EVD, * Participation agreement: * For adult participants (≥ 18 years old, emancipated or married): informed consent intended for the adult participant signed, * For minors ≥ 5 years old: informed consent intended for the parent(s)/legal guardian signed by at least one of the two parents or the legal guardian and assent form intended for the minor participant completed. In cellular immunological sub-study: * Adult participants in the parent study ≥ 18 years old, * Accept to participate in this sub-study * Negative blood EBOV PCR Exclusion Criteria: * Absence of possible follow-up over 12 months from a logistical or geographical point of view (only for cured patients); * Non-residents in the DRC; * Impossibility of complying with the requirements and procedures of the study in the opinion of the investigator; * Inability to consent.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Ebola virus disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beni Hospital
Beni, Democratic Republic of the Congo
-
Butembo Hospital
Butembo, Democratic Republic of the Congo
-
Mambasa Hospital
Mambasa, Democratic Republic of the Congo
-
Mangina Hospital
Beni, Democratic Republic of the Congo
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Ebola vaccine trial aims to shield frontline workers in congo
- Ebola vaccine in a nasal spray? early trial halted
- Ebola vaccine memory under the microscope: how long does it last?
- Could a vaccine and antibody combo stop ebola after exposure?
- UK volunteers test new ebola vaccine combo in Early-Stage trial
- Ebola antibody cocktail made available in emergency outbreak